The FDA identified a recall of smartphone apps for Dexcom (Nasdaq:DXCM) continuous glucose monitors as the most serious type.

Dexcom (Nasdaq:DXCM) today announced plans to unveil its Smart Basal integrated titration module for insulin delivery.

BD (NYSE:BDX) announced that it expanded its Class I voluntary recall for its Alaris Pump Module model 8100 infusion system.

Insulet (Nasdaq:PODD) has its eyes on future expansion in new geographies, according to some of its leading executives.

Elutia announced today that it agreed to sell its bioenvelope technologies to Boston Scientific for $88 million.

Johnson & Johnson announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.

A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts.